Genscript Biotech Corporation (GNNSF)
USD 1.5
(-21.0%)
USD 1.5
(-21.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 409.55 Million USD | 35.0% |
| 2022 | 304.08 Million USD | 0.2% |
| 2021 | 303.48 Million USD | 18.6% |
| 2020 | 255.89 Million USD | 41.93% |
| 2019 | 180.29 Million USD | 13.72% |
| 2018 | 158.53 Million USD | 51.58% |
| 2017 | 104.59 Million USD | 37.21% |
| 2016 | 76.22 Million USD | 33.55% |
| 2015 | 57.07 Million USD | 29.43% |
| 2014 | 44.09 Million USD | 15.64% |
| 2013 | 38.13 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 153.49 Million USD | 0.0% |
| 2024 Q1 | 153.49 Million USD | -34.62% |
| 2023 Q2 | 175.04 Million USD | 100.0% |
| 2023 Q1 | 87.52 Million USD | -32.12% |
| 2023 FY | 410.51 Million USD | 35.0% |
| 2023 Q4 | 234.76 Million USD | 100.22% |
| 2023 Q3 | 117.25 Million USD | -33.02% |
| 2022 Q3 | 67.79 Million USD | -61.26% |
| 2022 Q2 | 174.99 Million USD | 107.71% |
| 2022 Q1 | 84.24 Million USD | -48.8% |
| 2022 FY | 304.08 Million USD | 0.2% |
| 2022 Q4 | 128.94 Million USD | 90.2% |
| 2021 Q4 | 164.55 Million USD | 128.71% |
| 2021 Q1 | 69.3 Million USD | -53.06% |
| 2021 FY | 303.48 Million USD | 18.6% |
| 2021 Q3 | 71.94 Million USD | -48.07% |
| 2021 Q2 | 138.53 Million USD | 99.89% |
| 2020 Q4 | 147.66 Million USD | 99.93% |
| 2020 Q2 | 108.32 Million USD | 100.27% |
| 2020 Q1 | 54.08 Million USD | -46.42% |
| 2020 FY | 255.89 Million USD | 41.93% |
| 2020 Q3 | 73.86 Million USD | -31.81% |
| 2019 Q3 | 50.69 Million USD | -35.27% |
| 2019 Q4 | 100.93 Million USD | 99.11% |
| 2019 FY | 180.29 Million USD | 13.72% |
| 2019 Q1 | 39.44 Million USD | 2.24% |
| 2019 Q2 | 78.31 Million USD | 98.52% |
| 2018 Q3 | 38.58 Million USD | -5.15% |
| 2018 Q2 | 40.68 Million USD | 0.0% |
| 2018 Q4 | 38.58 Million USD | 0.0% |
| 2018 Q1 | 40.68 Million USD | 31.97% |
| 2018 FY | 158.53 Million USD | 51.58% |
| 2017 Q3 | 30.82 Million USD | 43.61% |
| 2017 FY | 104.59 Million USD | 37.21% |
| 2017 Q4 | 30.82 Million USD | 0.0% |
| 2017 Q2 | 21.46 Million USD | 0.0% |
| 2017 Q1 | 21.46 Million USD | 6.45% |
| 2016 Q1 | 17.94 Million USD | 18.79% |
| 2016 FY | 76.22 Million USD | 33.55% |
| 2016 Q4 | 20.16 Million USD | 0.0% |
| 2016 Q3 | 20.16 Million USD | 12.35% |
| 2016 Q2 | 17.94 Million USD | 0.0% |
| 2015 Q3 | 15.11 Million USD | 12.52% |
| 2015 Q1 | 13.42 Million USD | 18.08% |
| 2015 Q4 | 15.11 Million USD | 0.0% |
| 2015 FY | 57.07 Million USD | 29.43% |
| 2015 Q2 | 13.42 Million USD | 0.0% |
| 2014 Q1 | 10.67 Million USD | 0.0% |
| 2014 FY | 44.09 Million USD | 15.64% |
| 2014 Q4 | 11.37 Million USD | 0.0% |
| 2014 Q3 | 11.37 Million USD | 6.52% |
| 2014 Q2 | 10.67 Million USD | 0.0% |
| 2013 FY | 38.13 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 16791940.918% |
| Evofem Biosciences, Inc. | 11.7 Million USD | -3398.659% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 128282.794% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | -243.851% |
| Qrons Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 1687.538% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 848756.209% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 329717.468% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | -2630.535% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -13202769.117% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | -4081.672% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -623002.787% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 1199376.72% |
| Mesoblast Limited | -35.16 Million USD | 1264.562% |
| Marizyme, Inc. | 457.7 Thousand USD | -89380.273% |
| Genus plc | 178.7 Million USD | -129.185% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | -86.072% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -658070.218% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -99750.792% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 3723309.091% |
| ContraFect Corporation | -154 Thousand USD | 266043.506% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 819206.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -533443.075% |
| IMV Inc. | -962.29 Thousand USD | 42659.893% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 105790.824% |
| MultiCell Technologies, Inc. | 49.32 USD | -830399332.279% |
| ONE Bio Corp. | 20.12 Million USD | -1935.001% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | -917.144% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -837431.697% |
| Q BioMed Inc. | -8988.00 USD | 4556764.441% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | -1349.489% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 2655396.94% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | -823.294% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 35976.23% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -584975.714% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 8270556.381% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -291396.797% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 420089.745% |
| GB Sciences, Inc. | -624.00 USD | 65633593.59% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 476169.419% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 94.583% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 196900580.769% |
| Enzolytics Inc. | 30.7 Thousand USD | -1333601.316% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -84793.239% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 63.053% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 79700.591% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -66236.834% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 4624682.204% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 488541.126% |
| Kadimastem Ltd | -630.13 Thousand USD | 65094.176% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -41353.53% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | -4161.294% |
| BioStem Technologies, Inc. | 15.42 Million USD | -2555.151% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 3460623.87% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -231862.506% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -231862.506% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | -30077.586% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 1412351.724% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -90903.082% |
| SYBLEU INC | 11.69 Thousand USD | -3501550.137% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | -8787.869% |
| Bioxytran, Inc. | -8285.00 USD | 4943407.182% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 109899.732% |
| Neutra Corp. | 14.33 Thousand USD | -2856914.301% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 499554.878% |
| PureTech Health plc | -1.6 Million USD | 25649.158% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 41004.742% |
| IXICO plc | 3.27 Million USD | -12424.557% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 59113.401% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 22967.281% |
| CSL Limited | 7.7 Billion USD | 94.685% |
| Cellectis S.A. | 18 Thousand USD | -2275194.444% |